US2013295046A1PendingUtilityA1
Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
Est. expirySep 21, 2024(expired)· nominal 20-yr term from priority
Inventors:Hideho Okada
A61K 38/17C07K 14/7155C07K 14/4705A61K 9/0019C07K 14/4703C07K 14/705A61P 35/00A61P 37/04A61P 43/00A61P 25/00A61K 39/39A61K 2039/55566A61K 2039/70A61K 38/2086A61K 38/177A61K 38/1709A61K 2039/572A61K 2039/55583A61K 40/414A61K 40/24A61K 40/19A61K 2239/47
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, and a WT1 peptide.Join the waitlist — get patent alerts
Track US2013295046A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.